DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes

Area of Science:

• Endocrinology
• Genetics
• Oncology

Background:

• Cancer genetic risk assessment is expanding with new gene discoveries.
• Multiple Endocrine Neoplasia syndromes benefit from identifying causative genes for endocrine tumor susceptibility.
• Primary hyperparathyroidism (PHPT) is linked to MEN syndromes and can occur as familial clusters.

Purpose of the Study:

• To guide healthcare providers unfamiliar with genetic testing.
• To introduce concepts of genetic diagnosis for endocrine disorders.
• To detail the role and utility of DNA-based diagnosis for congenital PHPT.

Main Methods:

• Review of genetic testing principles and applications.
• Focus on DNA-based diagnostic utility in congenital PHPT.
• Discussion of when and how to perform genetic testing for PHPT.

Main Results:

• Identification of cancer-related genes aids genetic risk assessment.
• Genetic mutations are key to susceptibility in endocrine tumors.
• Care options are available for hereditary PHPT patients and families.

Conclusions:

• Systematic genetic risk assessment is increasingly important for hereditary PHPT.
• DNA-based diagnosis is practical for congenital PHPT.
• Recommendations are provided for managing suspected or known familial PHPT cases.